SDM laser effective for CSC

Article

According to recently published data, an 810 nm subthreshold diode micropulse (SDM) laser is effective in the treatment of chronic central serous chorioretinopathy (CSC).

According to recently published data, an 810 nm subthreshold diode micropulse (SDM) laser is effective in the treatment of chronic central serous chorioretinopathy (CSC).

The study, performed by Dr Luiz Roisman et al. (Federal University of Sao Paulo, Brazil), included 15 patients in total who were randomized into two groups to either receive SDM laser treatment or a sham procedure.

Ten patients received SDM laser treatment along the detached area, the remaining five patients received sham treatment. At 3 months follow up, the best-corrected visual acuity (BCVA) was found to be significantly improved in the laser treatment group. All patients allocated to the sham group required treatment after 3 months. Central macular thickness was noted to be better in both groups.

It was concluded that SDM laser treatment was effective in the treatment of chronic CSC without causing any damage to the retina.

For more detailed information please view the abstract in Ophthalmic Surgery, Lasers and Imaging.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.